Suchergebnisse - "Subklewe, Marion"

PubPharm (274)

101

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

enthalten in: Blood advances | 2022

von Iacoboni, G. | Rejeski, K. | Villacampa, G. | +19

102

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML

enthalten in: Biomarker research | 2022

von Köhnke, T. | Liu, X. | Haubner, S. | +6

103

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML

enthalten in: Biomarker Research | 2022

von Köhnke, T. | Liu, X. | Haubner, S. | +6

104

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

enthalten in: Journal for immunotherapy of cancer | 2022

von Rejeski, K. | Perez, A. | Iacoboni, G. | +17

105

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment

enthalten in: Blood advances | 2022

von Schoeberl, F. | Tiedt, S. | Schmitt, A. | +12

106

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells

enthalten in: Neurology | 2022

von Karschnia, P. | Rejeski, K. | Winkelmann, M. | +10

107

Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide

enthalten in: Europäisches Patentamt | 2022

von AUGSBERGER CHRISTIAN | KLEIN CHRISTIAN | SUBKLEWE MARION

108

Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition

enthalten in: Europäisches Patentamt | 2022

von HOPFNER KARL-PETER | SUBKLEWE MARION | MAGAUER NADINE | +1

109

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia : Experience of the European LeukemiaNet MRD Working Party

enthalten in: HemaSphere | 2022

von Tettero, J. | Freeman, S. | Buecklein, V. | +22

ErratumIn: Hemasphere. 2022 Feb 23;6(3):e703. - PMID 35224454

110

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment : RECIL vs. Lugano vs. metabolic tumor assessment

enthalten in: Frontiers in oncology | 2022

von Winkelmann, M. | Bücklein, V. | Blumenberg, V. | +10